Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (231-240 of 337) with videos related to

Pageof 34
Sort By:
Nature Communications|November 28, 2023
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01Yunda Huang, Lily Zhang, Shelly Karuna, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2013
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras, Guido Ferrari, Xiaoying Shen, et al.
Nature Medicine|September 1, 2015
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersHolly Janes, Joshua T Herbeck, Sodsai Tovanabutra, et al.
Cell Host & Microbe|July 16, 2022
HLA-B∗46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotypeShuying S Li, Andrew Hickey, Shida Shangguan, et al.
Journal of Virology|August 23, 2019
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine TrialShuying S Li, Peter B Gilbert, Lindsay N Carpp, et al.
The Lancet. HIV|November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trialSusan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
Plos One|September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsYunda Huang, Dean Follmann, Martha Nason, et al.
Journal of AIDS & Clinical Research|November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Clinical and Vaccine Immunology : CVI|September 22, 2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8<sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNAShuying S Li, Nidhi K Kochar, Marnie Elizaga, et al.
Pageof 34

Showing results (231-240 of 337) with videos related to

Sort By:
Pageof 34
Nature Communications|November 28, 2023
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01Yunda Huang, Lily Zhang, Shelly Karuna, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2013
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras, Guido Ferrari, Xiaoying Shen, et al.
Nature Medicine|September 1, 2015
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersHolly Janes, Joshua T Herbeck, Sodsai Tovanabutra, et al.
Cell Host & Microbe|July 16, 2022
HLA-B∗46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotypeShuying S Li, Andrew Hickey, Shida Shangguan, et al.
Journal of Virology|August 23, 2019
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine TrialShuying S Li, Peter B Gilbert, Lindsay N Carpp, et al.
The Lancet. HIV|November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trialSusan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
Plos One|September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsYunda Huang, Dean Follmann, Martha Nason, et al.
Journal of AIDS & Clinical Research|November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Clinical and Vaccine Immunology : CVI|September 22, 2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8<sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNAShuying S Li, Nidhi K Kochar, Marnie Elizaga, et al.
Pageof 34